Brokerages expect Vistagen Therapeutics Inc (NASDAQ:VTGN) to post ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings of ($0.15) per share in the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The business is scheduled to announce its next earnings results on Tuesday, June 23rd.
On average, analysts expect that Vistagen Therapeutics will report full-year earnings of ($0.52) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will report earnings of ($0.44) per share. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Vistagen Therapeutics.
Several research firms recently commented on VTGN. Maxim Group reaffirmed a “buy” rating and set a $1.00 price objective on shares of Vistagen Therapeutics in a research report on Friday. Zacks Investment Research raised Vistagen Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, ValuEngine raised Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 3rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $0.85.
Shares of Vistagen Therapeutics stock traded down $0.02 during trading on Friday, hitting $0.52. 829,537 shares of the company’s stock traded hands, compared to its average volume of 1,274,114. Vistagen Therapeutics has a 1 year low of $0.29 and a 1 year high of $1.49. The stock has a market capitalization of $26.77 million, a P/E ratio of -0.89 and a beta of 0.31. The business has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.55.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Featured Article: What is a resistance level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.